The Paragon of Profiling

Cofactor Genomics Inc. and NIH’s National Cancer Institute (NCI) partnered last month to clinically validate Cofactor’s Paragon RNA profiling assay, which could expand immuno-oncology diagnostics and drug development with its machine learning-driven identification of immune cell subsets in solid tumor samples.

Immune cell profiling of tumors, including the type and number of immune cells, gives clinicians and drug developers information about whether a targeted therapy is having the desired antitumor immune response. ...